Screener Summaries Updates Institutions Sign In More Updates › Other Events › RGNT Other Events · Jul 15, 2026
On July 15, 2026, Regentis Biomaterials Ltd. announced it received European regulatory approval for a new GelrinC… RGNT Regentis Biomaterials Ltd.
On July 15, 2026, Regentis Biomaterials Ltd. announced it received European regulatory approval for a new GelrinC manufacturing process. This process increases production yield by 400% and supports the company's upcoming European commercial launch. The company operates in the biomaterials industry and develops medical-grade materials.
More from Regentis Biomaterials Ltd. Regentis Biomaterials reported a net loss of $2.6 million, or $0.44 per share, for the six months ended June 30, 2026… Sep 11, 2026 Regentis Biomaterials Ltd. announced that the Japan Patent Office has issued a Notice of Allowance for its proprietary… Jul 20, 2026 On July 9, 2026, Regentis Biomaterials Ltd. announced that shareholders approved all fourteen proposals presented at… Jul 9, 2026 Regentis Biomaterials Ltd. adjourned its Annual General Meeting of Shareholders, originally scheduled for July 2… Jul 2, 2026 Regentis Biomaterials Ltd. entered into definitive securities purchase agreements on June 17, 2026, to issue and sell… Jun 18, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
